Burning Rock Biotech (BNR) Set to Post Quarterly Earnings on Tuesday

Burning Rock Biotech (NASDAQ:BNR) is projected to announce its Q3 2026 resultson Tuesday, November 17th. Analysts expect the company to post earnings of ($0.3412) per share and revenue of $19.20 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings data on Thursday, September 10th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. Burning Rock Biotech had a negative return on equity of 12.98% and a negative net margin of 13.60%. The business had revenue of $19.84 million during the quarter, compared to the consensus estimate of $19.21 million.

Burning Rock Biotech Trading Down 7.7%

Shares of BNR opened at $12.39 on Tuesday. Burning Rock Biotech has a 1 year low of $6.79 and a 1 year high of $41.72. The stock has a market cap of $130.34 million, a P/E ratio of -14.24 and a beta of 1.50. The stock’s 50-day moving average price is $13.51 and its two-hundred day moving average price is $15.95.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Burning Rock Biotech to a “hold” rating in a report on Saturday, October 24th. Weiss Ratings upgraded shares of Burning Rock Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Burning Rock Biotech has an average rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech Limited is a biotechnology company focused on precision oncology. The company develops and commercializes next-generation sequencing (NGS) tests designed to help detect cancer, guide treatment decisions and monitor patients during therapy.

Its offerings include tissue- and blood-based genomic testing for cancer patients, as well as tests intended to support therapy selection, treatment monitoring and the identification of biomarkers relevant to targeted medicines and immunotherapies.